Zerbini O, Recchia G, Fabbri L
Clin Ter. 1990 Mar 31;132(6 Suppl):451-5.
The clinical development of any drug used in the treatment of brain-ageing, poses many methodological problems regarding the difficulty in defining precisely the pathology, both from the point of view of diagnostic and of terminology, the lack of specific parameters for assessing the therapeutic efficacy and the difficulty of establishing homogeneous trial sample, since the geriatric population is a very heterogeneous whole. The authors, in the light of the research done, state their methodology and give their directives; among them: common training for all the examiners, in order to make execution and classification of the tests extremely homogeneous the drug is evaluated through psychometric tests, which analyze the patient both physically and mentally.
任何用于治疗脑老化的药物的临床开发，都存在许多方法学问题，从诊断和术语角度来看，难以精确界定病理学，缺乏评估治疗效果的具体参数，且由于老年人群体非常 heterogeneous ，难以建立同质化的试验样本。作者根据已开展的研究，阐述了他们的方法并给出了指导意见；其中包括：对所有检查人员进行共同培训，以使测试的执行和分类极其同质化，通过心理测量测试评估药物，该测试从身体和心理两方面对患者进行分析。 （注：原文中“heterogeneous”未翻译完整，推测可能是“异质性的”意思 ）
